alexa A Case of Merkel Cell Carcinoma Treated with Anti-CTLA-
ISSN: 2165-7920

Journal of Clinical Case Reports
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

A Case of Merkel Cell Carcinoma Treated with Anti-CTLA-4 Antibody (Ipilimumab)

Blake A Williams1, Matthew E Hardee2, Laura F Hutchins3, Sara Shalin1,4 and Ling Gao1*
1Department of Dermatology, University of Arkansas for Medical Sciences, USA
2Department of Radiation Oncology, University of Arkansas for Medical Sciences, USA
3Department of Medicine, University of Arkansas for Medical Sciences, USA
4Department of Pathology, University of Arkansas for Medical Sciences, USA
Corresponding Author : Ling Gao
Department of Dermatology
University of Arkansas for Medical Sciences, USA
Tel: +1 501-686-7000
Fax: 501-526-4474
E-mail: [email protected]
Received: November 08, 2015; Accepted: December 02, 2015; Published: December 09, 2015
Citation: Williams BA, Hardee ME, Hutchins LF, Shalin S, Gao L (2015) A Case of Merkel Cell Carcinoma Treated with Anti-CTLA-4 Antibody (Ipilimumab). J Clin Case Rep 5:659. doi:10.4172/2165-7920.1000659
Copyright: © 2015 Williams BA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at Pubmed, Scholar Google
 

Abstract

Merkel Cell Carcinoma (MCC) is a rare but aggressive skin cancer. Similar to melanoma, infiltration of CD8+ T cells is associated with an improved prognosis, which provides rationale for immunotherapy in MCC. This manuscript reports the first application of ipilimumab in the treatment of a MCC patient. In this case, combination treatment of a stage IV MCC patient with ipilimumab, radiotherapy, and chemotherapy resulted in stable disease. Unfortunately, the patient passed away from an unrelated cardiac event prior to being able to be fully evaluated for the effects of ipilimumab. Immunotherapy represents a promising treatment option for advanced cancers. Ongoing clinical trials should provide information regarding the efficacy of immunotherapy in otherwise often-lethal metastatic MCC.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords